Molecular Actions of PPARα in Lipid Metabolism and Inflammation.

Peroxisome proliferator-activated receptor α (PPARα) is a nuclear receptor of clinical interest as a drug target in various metabolic disorders. PPARα also exhibits marked anti-inflammatory capacities. The first-generation PPARα agonists, the fibrates, have however been hampered by drug-drug interaction issues, statin drop-in, and ill-designed cardiovascular intervention trials. Notwithstanding, understanding the molecular mechanisms by which PPARα works will enable control of its activities as a drug target for metabolic diseases with an underlying inflammatory component. Given its role in reshaping the immune system, the full potential of this nuclear receptor subtype as a versatile drug target with high plasticity becomes increasingly clear, and a novel generation of agonists may pave the way for novel fields of applications.

[1]  J. Eeckhoute,et al.  Daytime variation of perioperative myocardial injury in cardiac surgery and its prevention by Rev-Erbα antagonism: a single-centre propensity-matched cohort study and a randomised study , 2018, The Lancet.

[2]  S. Yamashita,et al.  Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial , 2018, Diabetes Care.

[3]  H. Hammad,et al.  Co-Activation of Glucocorticoid Receptor and Peroxisome Proliferator-Activated Receptor-γ in Murine Skin Prevents Worsening of Atopic March. , 2017, The Journal of investigative dermatology.

[4]  M. Yoneda,et al.  Current and future pharmacological therapies for NAFLD/NASH , 2017, Journal of Gastroenterology.

[5]  M. Kurrer,et al.  PPARγ in dendritic cells and T cells drives pathogenic type-2 effector responses in lung inflammation , 2017, The Journal of experimental medicine.

[6]  S. Yamashita,et al.  Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial. , 2017, Journal of clinical lipidology.

[7]  G. Freeman,et al.  Enhancing CD8+ T Cell Fatty Acid Catabolism within a Metabolically Challenging Tumor Microenvironment Increases the Efficacy of Melanoma Immunotherapy. , 2017, Cancer cell.

[8]  Jing Wang,et al.  PPARα activation protects against cholestatic liver injury , 2017, Scientific Reports.

[9]  T. Kaplan,et al.  Hierarchical role for transcription factors and chromatin structure in genome organization along adipogenesis , 2017, The FEBS journal.

[10]  S. Kaech,et al.  Reenergizing T cell anti-tumor immunity by harnessing immunometabolic checkpoints and machineries. , 2017, Current opinion in immunology.

[11]  S. Yamashita,et al.  Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia. , 2017, Atherosclerosis.

[12]  R. Takayanagi,et al.  Renoprotective effect of a novel selective PPARα modulator K-877 in db/db mice: A role of diacylglycerol-protein kinase C-NAD(P)H oxidase pathway. , 2017, Metabolism: clinical and experimental.

[13]  G. Camejo.  Phase 2 clinical trials with K-877 (pemafibrate): A promising selective PPAR-α modulator for treatment of combined dyslipidemia. , 2017, Atherosclerosis.

[14]  S. Kersten,et al.  The role and regulation of the peroxisome proliferator activated receptor alpha in human liver. , 2017, Biochimie.

[15]  G. Oh,et al.  PPAR-α Activation Mediates Innate Host Defense through Induction of TFEB and Lipid Catabolism , 2017, The Journal of Immunology.

[16]  J. Eeckhoute,et al.  Distinct but complementary contributions of PPAR isotypes to energy homeostasis. , 2017, The Journal of clinical investigation.

[17]  H. Shimano,et al.  Effects of K-877, a novel selective PPARα modulator, on small intestine contribute to the amelioration of hyperlipidemia in low-density lipoprotein receptor knockout mice. , 2017, Journal of pharmacological sciences.

[18]  B. Lambrecht,et al.  PPAR-γ promotes type 2 immune responses in allergy and nematode infection , 2017, Science Immunology.

[19]  K. Moore,et al.  Store-Operated Ca2+ Entry Controls Induction of Lipolysis and the Transcriptional Reprogramming to Lipid Metabolism. , 2017, Cell metabolism.

[20]  C. Brocker,et al.  Hepatocyte-specific PPARA expression exclusively promotes agonist-induced cell proliferation without influence from nonparenchymal cells. , 2017, American journal of physiology. Gastrointestinal and liver physiology.

[21]  A. Filer,et al.  Priming in response to pro-inflammatory cytokines is a feature of adult synovial but not dermal fibroblasts , 2017, Arthritis Research & Therapy.

[22]  S. Matoba,et al.  Activation of PPAR-α in the early stage of heart failure maintained myocardial function and energetics in pressure-overload heart failure. , 2017, American journal of physiology. Heart and circulatory physiology.

[23]  Michael W. Hankins,et al.  Biliverdin Reductase A Attenuates Hepatic Steatosis by Inhibition of Glycogen Synthase Kinase (GSK) 3β Phosphorylation of Serine 73 of Peroxisome Proliferator-activated Receptor (PPAR) α* , 2016, The Journal of Biological Chemistry.

[24]  T. Aoyama,et al.  Activation of PPARα by Fatty Acid Accumulation Enhances Fatty Acid Degradation and Sulfatide Synthesis. , 2016, The Tohoku journal of experimental medicine.

[25]  J. Tavernier,et al.  Chromatin recruitment of activated AMPK drives fasting response genes co-controlled by GR and PPARα , 2016, Nucleic acids research.

[26]  Maxim N. Artyomov,et al.  Type 1 Interferons Induce Changes in Core Metabolism that Are Critical for Immune Function. , 2016, Immunity.

[27]  B. Staels,et al.  The novel selective PPARα modulator (SPPARMα) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis. , 2016, Atherosclerosis.

[28]  Philippe Lehert,et al.  Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. , 2016, Gastroenterology.

[29]  S. Cuzzocrea,et al.  PPAR-α Modulates the Anti-Inflammatory Effect of Melatonin in the Secondary Events of Spinal Cord Injury , 2016, Molecular Neurobiology.

[30]  S. Ramakrishnan,et al.  PPARα (Peroxisome Proliferator-activated Receptor α) Activation Reduces Hepatic CEACAM1 Protein Expression to Regulate Fatty Acid Oxidation during Fasting-refeeding Transition* , 2016, The Journal of Biological Chemistry.

[31]  W. Wahli,et al.  Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD , 2016, Gut.

[32]  F. Villarroya,et al.  Sirt1 mediates the effects of a short-term high-fat diet on the heart. , 2015, The Journal of nutritional biochemistry.

[33]  Wang-Soo Lee,et al.  Peroxisome Proliferator-Activated Receptors and the Heart: Lessons from the Past and Future Directions , 2015, PPAR research.

[34]  S. Kersten,et al.  The impact of PPARα activation on whole genome gene expression in human precision cut liver slices , 2015, BMC Genomics.

[35]  J. Sadoshima,et al.  PPARα Association With Sirt1 Suppresses Cardiac Fatty Acid Metabolism in the Failing Heart , 2015 .

[36]  Hyunbae Kim,et al.  Lysine Acetylation of CREBH Regulates Fasting-Induced Hepatic Lipid Metabolism , 2015, Molecular and Cellular Biology.

[37]  D. Lalush,et al.  The ubiquitin ligase MuRF1 regulates PPARα activity in the heart by enhancing nuclear export via monoubiquitination , 2015, Molecular and Cellular Endocrinology.

[38]  V. Paradis,et al.  Liver microRNA-21 is overexpressed in non-alcoholic steatohepatitis and contributes to the disease in experimental models by inhibiting PPARα expression , 2015, Gut.

[39]  T. Hornemann,et al.  Fenofibrate lowers atypical sphingolipids in plasma of dyslipidemic patients: A novel approach for treating diabetic neuropathy? , 2015, Journal of clinical lipidology.

[40]  M. Schwab,et al.  The truncated splice variant of peroxisome proliferator-activated receptor alpha, PPARα-tr, autonomously regulates proliferative and pro-inflammatory genes , 2015, BMC Cancer.

[41]  B. Staels,et al.  Ketone Body Therapy Protects From Lipotoxicity and Acute Liver Failure Upon Pparα Deficiency. , 2015, Molecular endocrinology.

[42]  C. Mandarim-de-Lacerda,et al.  PPAR‐α agonist elicits metabolically active brown adipocytes and weight loss in diet‐induced obese mice , 2015, Cell biochemistry and function.

[43]  H. Chung,et al.  Age-related sensitivity to endotoxin-induced liver inflammation: Implication of inflammasome/IL-1β for steatohepatitis , 2015, Aging cell.

[44]  T. Velkov,et al.  Fatty Acid-binding Proteins 1 and 2 Differentially Modulate the Activation of Peroxisome Proliferator-activated Receptor α in a Ligand-selective Manner* , 2015, The Journal of Biological Chemistry.

[45]  EscuderoPaula,et al.  Combined sub-optimal doses of rosuvastatin and bexarotene impair angiotensin II-induced arterial mononuclear cell adhesion through inhibition of Nox5 signaling pathways and increased RXR/PPARα and RXR/PPARγ interactions. , 2015 .

[46]  Philippe Lefebvre,et al.  Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. , 2015, Journal of hepatology.

[47]  B. Staels,et al.  The transrepressive activity of peroxisome proliferator‐activated receptor alpha is necessary and sufficient to prevent liver fibrosis in mice , 2014, Hepatology.

[48]  J. Cidlowski,et al.  One Hormone, Two Actions: Anti- and Pro-Inflammatory Effects of Glucocorticoids , 2014, Neuroimmunomodulation.

[49]  M. Netea,et al.  PPAR-alpha dependent regulation of vanin-1 mediates hepatic lipid metabolism. , 2014, Journal of hepatology.

[50]  K. De Bosscher,et al.  Giardia muris Infection in Mice Is Associated with a Protective Interleukin 17A Response and Induction of Peroxisome Proliferator-Activated Receptor Alpha , 2014, Infection and Immunity.

[51]  S. Kersten.  Integrated physiology and systems biology of PPARα , 2014, Molecular metabolism.

[52]  G. Watts,et al.  New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease , 2014, Expert opinion on pharmacotherapy.

[53]  Ze Zheng,et al.  Liver-enriched transcription factor CREBH interacts with peroxisome proliferator-activated receptor α to regulate metabolic hormone FGF21. , 2014, Endocrinology.

[54]  D. Hum,et al.  Hepatoprotective effects of the dual peroxisome proliferator‐activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis , 2013, Hepatology.

[55]  J. Eeckhoute,et al.  PPARalpha regulates the production of serum Vanin‐1 by liver , 2013, FEBS letters.

[56]  A. Shurlygina,et al.  Bezafibrate Causes Depression of the Immune Response and Increases the Sensitivity to Endotoxin in Association with Low Level of HDL and PPARα Activity in Hypertensive ISIAH Rats , 2013, Bulletin of Experimental Biology and Medicine.

[57]  E. Barroso,et al.  An overview of the crosstalk between inflammatory processes and metabolic dysregulation during diabetic cardiomyopathy. , 2013, International journal of cardiology.

[58]  M. Laville,et al.  Dual Peroxisome Proliferator–Activated Receptor α/δ Agonist GFT505 Improves Hepatic and Peripheral Insulin Sensitivity in Abdominally Obese Subjects , 2013, Diabetes Care.

[59]  M. Ricote,et al.  Retinoid X receptors in macrophage biology , 2013, Trends in Endocrinology & Metabolism.

[60]  D. Hardie,et al.  AMPK: A Target for Drugs and Natural Products With Effects on Both Diabetes and Cancer , 2013, Diabetes.

[61]  J. Fruchart,et al.  Selective peroxisome proliferator-activated receptorα modulators (SPPARMα): The next generation of peroxisome proliferator-activated receptor α-agonists , 2013, Cardiovascular Diabetology.

[62]  David W Ray,et al.  The circadian clock and asthma , 2013, Thorax.

[63]  S. Friedman,et al.  Post-transcriptional activation of PPAR alpha by KLF6 in hepatic steatosis. , 2013, Journal of hepatology.

[64]  J. Mckenney,et al.  Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting. , 2013, Journal of clinical lipidology.

[65]  B. Okopień,et al.  The Effect of Fenofibrate on Lymphocyte Release of Proinflammatory Cytokines and Systemic Inflammation in Simvastatin‐Treated Patients with Atherosclerosis and Early Glucose Metabolism Disturbances , 2013, Basic & clinical pharmacology & toxicology.

[66]  D. Ray,et al.  The role of the circadian clock in rheumatoid arthritis , 2013, Arthritis Research & Therapy.

[67]  A. Keech,et al.  Therapeutic Effects of PPARα Agonists on Diabetic Retinopathy in Type 1 Diabetes Models , 2012, Diabetes.

[68]  D. Mogilenko,et al.  Peroxisome Proliferator-activated Receptor α Positively Regulates Complement C3 Expression but Inhibits Tumor Necrosis Factor α-mediated Activation of C3 Gene in Mammalian Hepatic-derived Cells* , 2012, The Journal of Biological Chemistry.

[69]  Susanne Mandrup,et al.  PPARs: fatty acid sensors controlling metabolism. , 2012, Seminars in cell & developmental biology.

[70]  Y. Fujiki,et al.  Ligand‐dependent nucleo‐cytoplasmic shuttling of peroxisome proliferator‐activated receptors, PPARα and PPARγ , 2012, Genes to cells : devoted to molecular & cellular mechanisms.

[71]  W. Wahli,et al.  PPARs at the crossroads of lipid signaling and inflammation , 2012, Trends in Endocrinology & Metabolism.

[72]  J. Cidlowski,et al.  Proinflammatory actions of glucocorticoids: glucocorticoids and TNFα coregulate gene expression in vitro and in vivo. , 2012, Endocrinology.

[73]  P. O’Connor,et al.  Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience , 2012, Diabetologia.

[74]  J. Sadoshima,et al.  Suppression of ERR targets by a PPARα/Sirt1 complex in the failing heart , 2012, Cell cycle.

[75]  H. Wong,et al.  Reduced Peroxisome Proliferator-Activated Receptor &agr; Expression Is Associated With Decreased Survival and Increased Tissue Bacterial Load in Sepsis , 2012, Shock.

[76]  M. Willis,et al.  The story so far: post-translational regulation of peroxisome proliferator-activated receptors by ubiquitination and SUMOylation. , 2012, American journal of physiology. Heart and circulatory physiology.

[77]  H. Stunnenberg,et al.  Genome-Wide Profiling of Liver X Receptor, Retinoid X Receptor, and Peroxisome Proliferator-Activated Receptor α in Mouse Liver Reveals Extensive Sharing of Binding Sites , 2011, Molecular and Cellular Biology.

[78]  Yukio Sugimoto,et al.  Involvement of the Retinoid X Receptor Ligand in the Anti-Inflammatory Effect Induced by Peroxisome Proliferator-Activated Receptor γ Agonist In Vivo , 2011, PPAR research.

[79]  J. Sadoshima,et al.  PPARα-Sirt1 complex mediates cardiac hypertrophy and failure through suppression of the ERR transcriptional pathway. , 2011, Cell metabolism.

[80]  C. Glass,et al.  PPARs and lipid ligands in inflammation and metabolism. , 2011, Chemical reviews.

[81]  J. Cidlowski,et al.  Glucocorticoids Sensitize the Innate Immune System through Regulation of the NLRP3 Inflammasome* , 2011, The Journal of Biological Chemistry.

[82]  E. Bruckert,et al.  Effects of the New Dual PPARα/δ Agonist GFT505 on Lipid and Glucose Homeostasis in Abdominally Obese Patients With Combined Dyslipidemia or Impaired Glucose Metabolism , 2011, Diabetes Care.

[83]  J. Saver,et al.  Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis. , 2011, Atherosclerosis.

[84]  D. Rader,et al.  Peroxisome Proliferator-Activated Receptor-&agr; Activation Promotes Macrophage Reverse Cholesterol Transport Through a Liver X Receptor–Dependent Pathway , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[85]  J. Muntané,et al.  Human SREBP1c Expression in Liver Is Directly Regulated by Peroxisome Proliferator-activated Receptor α (PPARα)* , 2011, The Journal of Biological Chemistry.

[86]  C. Anderwald,et al.  A Combination of (ω–3) Polyunsaturated Fatty Acids, Polyphenols and L-Carnitine Reduces the Plasma Lipid Levels and Increases the Expression of Genes Involved in Fatty Acid Oxidation in Human Peripheral Blood Mononuclear Cells and HepG2 Cells , 2011, Annals of Nutrition and Metabolism.

[87]  S. Mandrup,et al.  Extensive chromatin remodelling and establishment of transcription factor ‘hotspots’ during early adipogenesis , 2011, The EMBO journal.

[88]  W. Wahli,et al.  Proline- and acidic amino acid-rich basic leucine zipper proteins modulate peroxisome proliferator-activated receptor α (PPARα) activity , 2011, Proceedings of the National Academy of Sciences.

[89]  Michael E. Miller,et al.  Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes , 2011 .

[90]  Y. Fujiki,et al.  Nuclear transport of peroxisome-proliferator activated receptor α. , 2011, Journal of biochemistry.

[91]  M. White,et al.  Feedback regulation of hepatic gluconeogenesis through modulation of SHP/Nr0b2 gene expression by Sirt1 and FoxO1. , 2011, American journal of physiology. Endocrinology and metabolism.

[92]  M. Lazar,et al.  Endogenous Ligands for Nuclear Receptors: Digging Deeper* , 2010, The Journal of Biological Chemistry.

[93]  Michael Müller,et al.  Peroxisome Proliferator-Activated Receptor Alpha Target Genes , 2010, PPAR research.

[94]  K. Ward,et al.  WY-14 643, a Selective PPARα Agonist, Induces Proinflammatory and Proangiogenic Responses in Human Ocular Cells , 2010, International journal of toxicology.

[95]  S. Mandrup,et al.  Molecular Mechanisms and Genome-Wide Aspects of PPAR Subtype Specific Transactivation , 2010, PPAR research.

[96]  Jianming Xu,et al.  Coactivators in PPAR-Regulated Gene Expression , 2010, PPAR research.

[97]  M. Schrader,et al.  Be different--the diversity of peroxisomes in the animal kingdom. , 2010, Biochimica et biophysica acta.

[98]  J. Cooney,et al.  Molecular Characterization of the Onset and Progression of Colitis in Inoculated Interleukin-10 Gene-Deficient Mice: A Role for PPARα , 2010, PPAR research.

[99]  E. Mazzon,et al.  PPAR-α Contributes to the Anti-Inflammatory Activity of Verbascoside in a Model of Inflammatory Bowel Disease in Mice , 2010, PPAR research.

[100]  B. Staels.  Fibrates in CVD: a step towards personalised medicine , 2010, The Lancet.

[101]  D. Grobbee,et al.  Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis , 2010, The Lancet.

[102]  Tetsuro Ito,et al.  Vaticanol C, a resveratrol tetramer, activates PPARα and PPARβ/δ in vitro and in vivo , 2010, Nutrition & metabolism.

[103]  B. Staels,et al.  Fibrates, Glitazones, and Peroxisome Proliferator–Activated Receptors , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[104]  John B Buse,et al.  Effects of combination lipid therapy in type 2 diabetes mellitus. , 2010, The New England journal of medicine.

[105]  Kevin A Peterson,et al.  Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus , 2011 .

[106]  M. V. Suresh,et al.  Leukotriene B4 Is a Physiologically Relevant Endogenous Peroxisome Proliferator-activated Receptor-α Agonist* , 2010, The Journal of Biological Chemistry.

[107]  P. D. de Groot,et al.  Profiling of promoter occupancy by PPARα in human hepatoma cells via ChIP-chip analysis , 2010, Nucleic acids research.

[108]  K. Cusi,et al.  Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome. , 2010, The Journal of clinical endocrinology and metabolism.

[109]  Songtao Yu,et al.  Review Nuclear Receptor Signaling | The Open Access Journal of the Nuclear Receptor Signaling Atlas PPARα: energy combustion, hypolipidemia, inflammation and cancer , 2022 .

[110]  B. Staels,et al.  SUMOylation of Human Peroxisome Proliferator-activated Receptor α Inhibits Its Trans-activity through the Recruitment of the Nuclear Corepressor NCoR* , 2009, The Journal of Biological Chemistry.

[111]  E. Mazzon,et al.  PPAR-α Contributes to the Anti-Inflammatory Activity of 17β-Estradiol , 2009, Journal of Pharmacology and Experimental Therapeutics.

[112]  M. Prentki,et al.  Glucose represses PPARαgene expression via AMP‐activated protein kinase but not via p38 mitogen‐activated protein kinase in the pancreatic β‐cell , 2009, Journal of diabetes.

[113]  L. Sanderson,et al.  Peroxisome Proliferator-Activated Receptor β/δ (PPARβ/δ) but Not PPARα Serves as a Plasma Free Fatty Acid Sensor in Liver , 2009, Molecular and Cellular Biology.

[114]  A. Grefhorst,et al.  Fenofibrate Simultaneously Induces Hepatic Fatty Acid Oxidation, Synthesis, and Elongation in Mice* , 2009, The Journal of Biological Chemistry.

[115]  W. Wahli,et al.  Sumoylated PPARalpha mediates sex-specific gene repression and protects the liver from estrogen-induced toxicity in mice. , 2009, The Journal of clinical investigation.

[116]  Michael Müller,et al.  Comparative Analysis of Gene Regulation by the Transcription Factor PPARα between Mouse and Human , 2009, PloS one.

[117]  John Turk,et al.  Identification of a Physiologically Relevant Endogenous Ligand for PPARα in Liver , 2009, Cell.

[118]  S. Cuzzocrea,et al.  THE ROLE OF ENDOGENOUS AND EXOGENOUS LIGANDS FOR THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA (PPAR-&agr;) IN THE REGULATION OF INFLAMMATION IN MACROPHAGES , 2009, Shock.

[119]  S. Lancel,et al.  Fenofibrate inhibits aldosterone-induced apoptosis in adult rat ventricular myocytes via stress-activated kinase-dependent mechanisms. , 2009, American journal of physiology. Heart and circulatory physiology.

[120]  G. Haegeman,et al.  PPARα blocks glucocorticoid receptor α-mediated transactivation but cooperates with the activated glucocorticoid receptor α for transrepression on NF-κB , 2009, Proceedings of the National Academy of Sciences.

[121]  Yan Wu,et al.  Peroxisome proliferator-activated receptor-gamma and retinoid X receptor agonists synergistically suppress proliferation of immortalized endometrial stromal cells. , 2009, Fertility and sterility.

[122]  Y. E. Chen,et al.  PPARs and the cardiovascular system. , 2009, Antioxidants & redox signaling.

[123]  R. Tukey,et al.  Opposing Roles of Peroxisome Proliferator-activated Receptor α and Growth Hormone in the Regulation of CYP4A11 Expression in a Transgenic Mouse Model* , 2009, The Journal of Biological Chemistry.

[124]  K. Xiang,et al.  Fenofibrate reduces serum retinol-binding protein-4 by suppressing its expression in adipose tissue. , 2009, American journal of physiology. Endocrinology and metabolism.

[125]  J. V. Vanden Heuvel,et al.  Regulation of peroxisome proliferator-activated receptor-alpha by MDM2. , 2009, Toxicological sciences : an official journal of the Society of Toxicology.

[126]  F. Hsu,et al.  PPARalpha ligands inhibit radiation-induced microglial inflammatory responses by negatively regulating NF-kappaB and AP-1 pathways. , 2008, Free radical biology & medicine.

[127]  Yoshitomo Hamuro,et al.  Structure of the intact PPAR-γ–RXR-α nuclear receptor complex on DNA , 2008, Nature.

[128]  B. Staels,et al.  Intestine-specific regulation of PPARalpha gene transcription by liver X receptors. , 2008, Endocrinology.

[129]  Youming Li,et al.  A Val227Ala substitution in the peroxisome proliferator activated receptor alpha (PPAR alpha) gene associated with non‐alcoholic fatty liver disease and decreased waist circumference and waist‐to‐hip ratio , 2008, Journal of gastroenterology and hepatology.

[130]  Alberto Zambon,et al.  Fibrates and future PPARα agonists in the treatment of cardiovascular disease , 2008, Nature Clinical Practice Cardiovascular Medicine.

[131]  J. Inoue,et al.  PPARalpha gene expression is up-regulated by LXR and PXR activators in the small intestine. , 2008, Biochemical and biophysical research communications.

[132]  Peter Tontonoz,et al.  Integration of metabolism and inflammation by lipid-activated nuclear receptors , 2008, Nature.

[133]  Michael E. Miller,et al.  Effects of intensive glucose lowering in type 2 diabetes. , 2008, The New England journal of medicine.

[134]  Y. Kamei,et al.  Effect of Peroxisome Proliferator‐activated Receptor‐α Ligands in the Interaction Between Adipocytes and Macrophages in Obese Adipose Tissue , 2008, Obesity.

[135]  D. Mozaffarian,et al.  The perfect storm: obesity, adipocyte dysfunction, and metabolic consequences. , 2008, Clinical chemistry.

[136]  B. Staels,et al.  Systemic and distal repercussions of liver-specific peroxisome proliferator-activated receptor-alpha control of the acute-phase response. , 2008, Endocrinology.

[137]  M. Shimizu,et al.  Synergistic Effects of PPARγ Ligands and Retinoids in Cancer Treatment , 2008, PPAR research.

[138]  E. Tai,et al.  A natural polymorphism in peroxisome proliferator-activated receptor-alpha hinge region attenuates transcription due to defective release of nuclear receptor corepressor from chromatin. , 2008, Molecular endocrinology.

[139]  A. Kanda,et al.  Peroxisome proliferator-activated receptor alpha regulates skin inflammation and humoral response in atopic dermatitis. , 2008, The Journal of allergy and clinical immunology.

[140]  M. Pérez-Carreras,et al.  A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease. , 2008, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[141]  G. Gibbons,et al.  Peroxisome Proliferator-activated Receptor α Deficiency Abolishes the Response of Lipogenic Gene Expression to Re-feeding , 2008, Journal of Biological Chemistry.

[142]  E. Mazzon,et al.  Peroxisome Proliferator-Activated Receptor-α Contributes to the Anti-Inflammatory Activity of Glucocorticoids , 2008, Molecular Pharmacology.

[143]  Huan Huang,et al.  Glucose Directly Links to Lipid Metabolism through High Affinity Interaction with Peroxisome Proliferator-activated Receptor α* , 2008, Journal of Biological Chemistry.

[144]  Sui Huang,et al.  PPARα agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition , 2008, Proceedings of the National Academy of Sciences.

[145]  Xianlin Han,et al.  Nuclear receptors PPARβ/δ and PPARα direct distinct metabolic regulatory programs in the mouse heart , 2007 .

[146]  R. Arora,et al.  The role of fibrates in the prevention of cardiovascular disease--a pooled meta-analysis of long-term randomized placebo-controlled clinical trials. , 2007, American heart journal.

[147]  L. Sanderson,et al.  Comprehensive Analysis of PPARα-Dependent Regulation of Hepatic Lipid Metabolism by Expression Profiling , 2007, PPAR research.

[148]  M. Lane,et al.  Brain fatty acid synthase activates PPARα to maintain energy homeostasis , 2007 .

[149]  R. Villa-Bellosta,et al.  Cytotoxicity of peroxisome proliferator-activated receptor α and γ agonists in renal proximal tubular cell lines , 2007 .

[150]  T. Lundåsen,et al.  PPARα is a key regulator of hepatic FGF21 , 2007 .

[151]  S. Haulon,et al.  PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. , 2007, Cell metabolism.

[152]  J. V. Vanden Heuvel,et al.  Modulation of PPAR activity via phosphorylation. , 2007, Biochimica et biophysica acta.

[153]  E. Mazzon,et al.  ABSENCE OF FUNCTIONAL PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-&agr; ENHANCED ILEUM PERMEABILITY DURING EXPERIMENTAL COLITIS , 2007, Shock.

[154]  W. Wahli,et al.  Peroxisome proliferator-activated receptors (PPARs) in skin health, repair and disease. , 2007, Biochimica et biophysica acta.

[155]  D. Hum,et al.  Safety issues and prospects for future generations of PPAR modulators. , 2007, Biochimica et biophysica acta.

[156]  D. Kroetz,et al.  Cytochrome P450 Eicosanoids are Activators of Peroxisome Proliferator-Activated Receptor α , 2007, Drug Metabolism and Disposition.

[157]  Daniel R. Jeske,et al.  Fenofibrate represses interleukin-17 and interferon-gamma expression and improves colitis in interleukin-10-deficient mice. , 2007, Gastroenterology.

[158]  B. Staels.  PPAR agonists and the metabolic syndrome. , 2007, Therapie.

[159]  F. Gonzalez,et al.  Critical Role for Transcription Coactivator Peroxisome Proliferator-activated Receptor (PPAR)-binding Protein/TRAP220 in Liver Regeneration and PPARα Ligand-induced Liver Tumor Development* , 2007, Journal of Biological Chemistry.

[160]  S. Kliewer,et al.  Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. , 2007, Cell metabolism.

[161]  J. Flier,et al.  Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. , 2007, Cell metabolism.

[162]  M. Adachi,et al.  The effects of statin and fibrate on lowering small dense LDL- cholesterol in hyperlipidemic patients with type 2 diabetes. , 2007, Journal of atherosclerosis and thrombosis.

[163]  S. Blüml,et al.  Expression of Heme Oxygenase-1 in Human Vascular Cells Is Regulated by Peroxisome Proliferator-Activated Receptors , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[164]  L. J. Hardies,et al.  Effects of peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus , 2007, Diabetologia.

[165]  T. A. Richardson,et al.  The Interleukin-1 receptor antagonist is a direct target gene of PPARalpha in liver. , 2007, Journal of hepatology.

[166]  K. Morimura,et al.  Peroxisome Proliferator-Activated Receptor α Regulates a MicroRNA-Mediated Signaling Cascade Responsible for Hepatocellular Proliferation , 2007, Molecular and Cellular Biology.

[167]  W. Wahli,et al.  Glycogen synthase 2 is a novel target gene of peroxisome proliferator-activated receptors , 2007, Cellular and Molecular Life Sciences.

[168]  S. Okamoto,et al.  Leptin Stimulates Fatty Acid Oxidation and Peroxisome Proliferator-Activated Receptor α Gene Expression in Mouse C2C12 Myoblasts by Changing the Subcellular Localization of the α2 Form of AMP-Activated Protein Kinase , 2007, Molecular and Cellular Biology.

[169]  G. Bergström,et al.  Importance of PPARα for the effects of growth hormone on hepatic lipid and lipoprotein metabolism , 2007 .

[170]  J. Auwerx,et al.  Peroxisome Proliferator-Activated Receptor-α Activation Inhibits Langerhans Cell Function1 , 2007, The Journal of Immunology.

[171]  S. Youssef,et al.  Peroxisome proliferator–activated receptor (PPAR)α expression in T cells mediates gender differences in development of T cell–mediated autoimmunity , 2007, The Journal of experimental medicine.

[172]  J. Altomonte,et al.  PPARα mediates the hypolipidemic action of fibrates by antagonizing FoxO1 , 2007 .

[173]  J. Plutzky,et al.  Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. , 2007, Circulation.

[174]  T. Olivecrona,et al.  Angiopoietin-like protein 4 converts lipoprotein lipase to inactive monomers and modulates lipase activity in adipose tissue , 2006, Proceedings of the National Academy of Sciences.

[175]  R. Seger,et al.  Interaction with MEK Causes Nuclear Export and Downregulation of Peroxisome Proliferator-Activated Receptor γ , 2006, Molecular and Cellular Biology.

[176]  M. J. Yoon,et al.  Adiponectin Increases Fatty Acid Oxidation in Skeletal Muscle Cells by Sequential Activation of AMP-Activated Protein Kinase, p38 Mitogen-Activated Protein Kinase, and Peroxisome Proliferator–Activated Receptor α , 2006, Diabetes.

[177]  Weimin He,et al.  Nuclear Receptor Expression Links the Circadian Clock to Metabolism , 2006, Cell.

[178]  E. Tai,et al.  The V227A polymorphism at the PPARA locus is associated with serum lipid concentrations and modulates the association between dietary polyunsaturated fatty acid intake and serum high density lipoprotein concentrations in Chinese women. , 2006, Atherosclerosis.

[179]  T. Matsunaga,et al.  Association of V227A PPAR&agr; polymorphism with altered serum biochemistry and alcohol drinking in Japanese men , 2006, Pharmacogenetics and genomics.

[180]  M. Racke,et al.  Peroxisome proliferator-activated receptor-α and retinoid X receptor agonists inhibit inflammatory responses of astrocytes , 2006, Journal of Neuroimmunology.

[181]  S. Mandrup,et al.  Glucose-induced repression of PPARα gene expression in pancreatic β-cells involves PP2A activation and AMPK inactivation , 2006 .

[182]  Béatrice Desvergne,et al.  From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. , 2006, Progress in lipid research.

[183]  Philippe Lefebvre,et al.  Sorting out the roles of PPARα in energy metabolism and vascular homeostasis , 2006 .

[184]  D. Dombrowicz,et al.  Acute Antiinflammatory Properties of Statins Involve Peroxisome Proliferator–Activated Receptor-α via Inhibition of the Protein Kinase C Signaling Pathway , 2006, Circulation research.

[185]  Min-Seon Kim,et al.  AMPK activation increases fatty acid oxidation in skeletal muscle by activating PPARalpha and PGC-1. , 2006, Biochemical and biophysical research communications.

[186]  J. W. Davis,et al.  The ribosomal protein rpL11 associates with and inhibits the transcriptional activity of peroxisome proliferator-activated receptor-alpha. , 2006, Toxicological sciences : an official journal of the Society of Toxicology.

[187]  F. Wondisford,et al.  Cross-talk between Thyroid Hormone Receptor and Liver X Receptor Regulatory Pathways Is Revealed in a Thyroid Hormone Resistance Mouse Model* , 2006, Journal of Biological Chemistry.

[188]  P Glasziou,et al.  Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial , 2005, The Lancet.

[189]  Y. Maehara,et al.  Short-Term Intensive Treatment for Donors with Hepatic Steatosis in Living-Donor Liver Transplantation , 2005, Transplantation.

[190]  R. Wanders,et al.  Bezafibrate increases very-long-chain acyl-CoA dehydrogenase protein and mRNA expression in deficient fibroblasts and is a potential therapy for fatty acid oxidation disorders. , 2005, Human molecular genetics.

[191]  G. Cline,et al.  Cardiac-specific overexpression of peroxisome proliferator-activated receptor-alpha causes insulin resistance in heart and liver. , 2005, Diabetes.

[192]  D. Crabb,et al.  Role of adiponectin in the protective action of dietary saturated fat against alcoholic fatty liver in mice , 2005, Hepatology.

[193]  A. E. Schultze,et al.  Administration of a PPARα agonist increases serum apolipoprotein A-V levels and the apolipoprotein A-V/apolipoprotein C-III ratio Published, JLR Papers in Press, May 16, 2005. DOI 10.1194/jlr.C500010-JLR200 , 2005, Journal of Lipid Research.

[194]  G. Gibbons,et al.  A role for PPARalpha in the control of SREBP activity and lipid synthesis in the liver. , 2005, The Biochemical journal.

[195]  J. V. Vanden Heuvel,et al.  Regulation of peroxisome proliferator-activated receptor alpha by protein kinase C. , 2005, Biochemistry.

[196]  Frank J. Gonzalez,et al.  Peroxisome proliferator-activated receptor-α and liver cancer: where do we stand? , 2005, Journal of Molecular Medicine.

[197]  C. Carlberg,et al.  The Human Peroxisome Proliferator-activated Receptor δ Gene is a Primary Target of 1α,25-Dihydroxyvitamin D3 and its Nuclear Receptor , 2005 .

[198]  A. Petrescu,et al.  Peroxisome Proliferator-activated Receptor α Interacts with High Affinity and Is Conformationally Responsive to Endogenous Ligands* , 2005, Journal of Biological Chemistry.

[199]  W. Wahli,et al.  Fluorescence Imaging Reveals the Nuclear Behavior of Peroxisome Proliferator-activated Receptor/Retinoid X Receptor Heterodimers in the Absence and Presence of Ligand*♦ , 2005, Journal of Biological Chemistry.

[200]  J. Schneider,et al.  "New" hepatic fat activates PPARalpha to maintain glucose, lipid, and cholesterol homeostasis. , 2005, Cell metabolism.

[201]  K. Oishi,et al.  CLOCK is involved in the circadian transactivation of peroxisome-proliferator-activated receptor α (PPARα) in mice , 2005 .

[202]  E. Tai,et al.  Polyunsaturated fatty acids interact with the PPARA-L162V polymorphism to affect plasma triglyceride and apolipoprotein C-III concentrations in the Framingham Heart Study. , 2005, The Journal of nutrition.

[203]  S. Mandrup,et al.  The Gene Encoding Acyl-CoA-binding Protein Is Subject to Metabolic Regulation by Both Sterol Regulatory Element-binding Protein and Peroxisome Proliferator-activated Receptor α in Hepatocytes* , 2005, Journal of Biological Chemistry.

[204]  Y. Bossé,et al.  The peroxisome proliferator-activated receptor alpha Leu162Val polymorphism influences the metabolic response to a dietary intervention altering fatty acid proportions in healthy men. , 2005, The American journal of clinical nutrition.

[205]  D. Piomelli,et al.  The Nuclear Receptor Peroxisome Proliferator-Activated Receptor-α Mediates the Anti-Inflammatory Actions of Palmitoylethanolamide , 2005, Molecular Pharmacology.

[206]  Ashok K. Chaudhary,et al.  Oxidized Omega-3 Fatty Acids Inhibit NF-&kgr;B Activation Via a PPAR&agr;-Dependent Pathway , 2004 .

[207]  C. Fontaine,et al.  Genomic and non-genomic interactions of PPARα with xenobiotic-metabolizing enzymes , 2004, Trends in Endocrinology & Metabolism.

[208]  W. Wahli,et al.  The Direct Peroxisome Proliferator-activated Receptor Target Fasting-induced Adipose Factor (FIAF/PGAR/ANGPTL4) Is Present in Blood Plasma as a Truncated Protein That Is Increased by Fenofibrate Treatment* , 2004, Journal of Biological Chemistry.

[209]  D. Gaudet,et al.  Association between the PPARα-L162V polymorphism and components of the metabolic syndrome , 2004, Journal of Human Genetics.

[210]  B. Staels,et al.  The Protein Kinase C Signaling Pathway Regulates a Molecular Switch between Transactivation and Transrepression Activity of the Peroxisome Proliferator-Activated Receptor α , 2004 .

[211]  W. Wahli,et al.  PPARα governs glycerol metabolism , 2004 .

[212]  B. Staels,et al.  Different ways to regulate the PPARα stability , 2004 .

[213]  I. Rusyn,et al.  Role of peroxisome proliferator-activated receptor-α (PPARα) in bezafibrate-induced hepatocarcinogenesis and cholestasis , 2004 .

[214]  D. Müller-Wieland,et al.  Association between the PPARalpha L162V polymorphism, plasma lipoprotein levels, and atherosclerotic disease in patients with diabetes mellitus type 2 and in nondiabetic controls. , 2004, American heart journal.

[215]  J. Yano,et al.  A Novel Selective Peroxisome Proliferator-Activated Receptor α Agonist, 2-Methyl-c-5-[4-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]butyl]-1,3-dioxane-r-2-carboxylic acid (NS-220), Potently Decreases Plasma Triglyceride and Glucose Levels and Modifies Lipoprotein Profiles in KK-Ay Mice , 2004, Journal of Pharmacology and Experimental Therapeutics.

[216]  W. Wahli,et al.  Be fit or be sick: peroxisome proliferator-activated receptors are down the road. , 2004, Molecular endocrinology.

[217]  J. Ward,et al.  Diminished Hepatocellular Proliferation in Mice Humanized for the Nuclear Receptor Peroxisome Proliferator-Activated Receptor α , 2004, Cancer Research.

[218]  P. So,et al.  Nuclear receptor corepressor RIP140 regulates fat accumulation. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[219]  Marc Montminy,et al.  PGC-1 promotes insulin resistance in liver through PPAR-α-dependent induction of TRB-3 , 2004, Nature Medicine.

[220]  Robert Kleemann,et al.  Global Suppression of IL-6-induced Acute Phase Response Gene Expression after Chronic in Vivo Treatment with the Peroxisome Proliferator-activated Receptor-α Activator Fenofibrate* , 2004, Journal of Biological Chemistry.

[221]  B. Cha,et al.  Peroxisomal-proliferator-activated receptor alpha activates transcription of the rat hepatic malonyl-CoA decarboxylase gene: a key regulation of malonyl-CoA level. , 2004, The Biochemical journal.

[222]  C. Urbich,et al.  PPAR&agr; Activators Inhibit Vascular Endothelial Growth Factor Receptor-2 Expression by Repressing Sp1-Dependent DNA Binding and Transactivation , 2004, Circulation research.

[223]  T. Tsukamoto,et al.  Tissue-Selective, Bidirectional Regulation of PEX11α and Perilipin Genes through a Common Peroxisome Proliferator Response Element , 2004, Molecular and Cellular Biology.

[224]  J. Zehnder,et al.  Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. , 2004, Journal of the American Society of Nephrology : JASN.

[225]  S. Kersten,et al.  Peroxisome proliferator-activated receptor α target genes , 2004, Cellular and Molecular Life Sciences CMLS.

[226]  B. Staels,et al.  Expression of adiponectin receptors in human macrophages and regulation by agonists of the nuclear receptors PPARα, PPARγ, and LXR , 2004 .

[227]  K. Umesono,et al.  Brain protection by resveratrol and fenofibrate against stroke requires peroxisome proliferator-activated receptor α in mice , 2003, Neuroscience Letters.

[228]  B. Staels,et al.  Peroxisome proliferator-activated receptors and inflammation: from basic science to clinical applications , 2003, International Journal of Obesity.

[229]  G. Etgen,et al.  PPAR ligands for metabolic disorders. , 2003, Current topics in medicinal chemistry.

[230]  D. Hadizadeh,et al.  Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome , 2003, Clinical pharmacology and therapeutics.

[231]  J. W. Davis,et al.  Heat shock protein-90 (Hsp90) acts as a repressor of peroxisome proliferator-activated receptor-α (PPARα) and PPARβ activity , 2003 .

[232]  D. Crabb,et al.  Peroxisome Proliferator-activated Receptor α (PPARα) Agonist Treatment Reverses PPARα Dysfunction and Abnormalities in Hepatic Lipid Metabolism in Ethanol-fed Mice* , 2003, Journal of Biological Chemistry.

[233]  Hitoshi Shimano,et al.  Cross-talk between peroxisome proliferator-activated receptor (PPAR) alpha and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. I. PPARs suppress sterol regulatory element binding protein-1c promoter through inhibition of LXR signaling. , 2003, Molecular endocrinology.

[234]  Dallas Jones,et al.  Peroxisome Proliferator-Activated Receptor α Negatively Regulates T-bet Transcription Through Suppression of p38 Mitogen-Activated Protein Kinase Activation1 , 2003, The Journal of Immunology.

[235]  K. Motojima,et al.  Fibrates and statins rapidly and synergistically induce pyruvate dehydrogenase kinase 4 mRNA in the liver and muscles of mice. , 2003, Biological & pharmaceutical bulletin.

[236]  H. Sone,et al.  Cross-talk between peroxisome proliferator-activated receptor (PPAR) alpha and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. II. LXRs suppress lipid degradation gene promoters through inhibition of PPAR signaling. , 2003, Molecular endocrinology.

[237]  Y. Bossé,et al.  The peroxisome proliferator-activated receptor alpha L162V mutation is associated with reduced adiposity. , 2003, Obesity research.

[238]  J. Peters,et al.  Bezafibrate is a dual ligand for PPARα and PPARβ: studies using null mice , 2003 .

[239]  Marc Montminy,et al.  TRB3: A tribbles Homolog That Inhibits Akt/PKB Activation by Insulin in Liver , 2003, Science.

[240]  Jeffrey A. Kramer,et al.  Transcription Profiling Distinguishes Dose-Dependent Effects in the Livers of Rats Treated with Clofibrate , 2003, Toxicologic pathology.

[241]  L. Pennacchio,et al.  Apolipoprotein A5, a Crucial Determinant of Plasma Triglyceride Levels, Is Highly Responsive to Peroxisome Proliferator-activated Receptor α Activators* , 2003, The Journal of Biological Chemistry.

[242]  J. V. Vanden Heuvel,et al.  Comprehensive analysis of gene expression in rat and human hepatoma cells exposed to the peroxisome proliferator WY14,643. , 2003, Toxicology and applied pharmacology.

[243]  James W. Anderson,et al.  Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). , 2003, Diabetes care.

[244]  A. Hamsten,et al.  Evidence That Peroxisome Proliferator–Activated Receptor Delta Influences Cholesterol Metabolism in Men , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[245]  Manabu T. Nakamura,et al.  Regulation of human Δ-6 desaturase gene transcription Published, JLR Papers in Press, January 16, 2003. DOI 10.1194/jlr.M200195-JLR200 , 2003, Journal of Lipid Research.

[246]  D. Haro,et al.  Control of human carnitine palmitoyltransferase II gene transcription by peroxisome proliferator-activated receptor through a partially conserved peroxisome proliferator-responsive element. , 2003, The Biochemical journal.

[247]  B. Staels,et al.  Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor. , 2003, Molecular endocrinology.

[248]  Robert Kleemann,et al.  Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFκB-C/EBP-β complex formation , 2003 .

[249]  Eric F. Johnson,et al.  Regulation of P450 4A expression by peroxisome proliferator activated receptors. , 2002, Toxicology.

[250]  D. Valle,et al.  PEX11α Is Required for Peroxisome Proliferation in Response to 4-Phenylbutyrate but Is Dispensable for Peroxisome Proliferator-Activated Receptor Alpha-Mediated Peroxisome Proliferation , 2002, Molecular and Cellular Biology.

[251]  E. Raspé,et al.  Identification of Rev-erbalpha as a physiological repressor of apoC-III gene transcription. , 2002, Journal of lipid research.

[252]  B. Staels,et al.  Peroxisome Proliferator-activated Receptor α (PPARα) Turnover by the Ubiquitin-Proteasome System Controls the Ligand-induced Expression Level of Its Target Genes* , 2002, The Journal of Biological Chemistry.

[253]  Pascal G. P. Martin,et al.  Comparative effect of fenofibrate on hepatic desaturases in wild-type and peroxisome proliferator-activated receptor α-deficient mice , 2002, Lipids.

[254]  K. Bulmer,et al.  Up-regulation of pyruvate dehydrogenase kinase isoform 4 (PDK4) protein expression in oxidative skeletal muscle does not require the obligatory participation of peroxisome-proliferator-activated receptor alpha (PPARalpha). , 2002, The Biochemical journal.

[255]  I. Yamaguchi,et al.  Stimulation of peroxisome-proliferator-activated receptor alpha (PPAR alpha) attenuates cardiac fibrosis and endothelin-1 production in pressure-overloaded rat hearts. , 2002, Clinical science.

[256]  S. Surapureddi,et al.  Identification of a transcriptionally active peroxisome proliferator-activated receptor α-interacting cofactor complex in rat liver and characterization of PRIC285 as a coactivator , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[257]  K. Kristiansen,et al.  The Gene Encoding the Acyl-CoA-binding Protein Is Activated by Peroxisome Proliferator-activated Receptor γ through an Intronic Response Element Functionally Conserved between Humans and Rodents* , 2002, The Journal of Biological Chemistry.

[258]  Y. Bossé,et al.  Influences of the PPARα-L162V polymorphism on plasma HDL2-cholesterol response of abdominally obese men treated with gemfibrozil , 2002, Genetics in Medicine.

[259]  K. Bulmer,et al.  Peroxisome-proliferator-activated receptor-α (PPARα) deficiency leads to dysregulation of hepatic lipid and carbohydrate metabolism by fatty acids and insulin , 2002 .

[260]  B. Staels,et al.  PPARs: Transcription Factors Controlling Lipid and Lipoprotein Metabolism , 2002, Annals of the New York Academy of Sciences.

[261]  Y. Bossé,et al.  Effect of apolipoprotein E, peroxisome proliferator-activated receptor alpha and lipoprotein lipase gene mutations on the ability of fenofibrate to improve lipid profiles and reach clinical guideline targets among hypertriglyceridemic patients. , 2002, Pharmacogenetics.

[262]  O. Sato,et al.  Dual Promoter Structure of Mouse and Human Fatty Acid Translocase/CD36 Genes and Unique Transcriptional Activation by Peroxisome Proliferator-activated Receptor α and γ Ligands* , 2002, The Journal of Biological Chemistry.

[263]  Y. Jamshidi,et al.  Characterization of the Human PPAR Promoter : Identification of a Functional Nuclear Receptor Response Element , 2002 .

[264]  W. V. Berghe,et al.  DNA Binding-Independent Induction of IκBα Gene Transcription by PPARα , 2002 .

[265]  B. Staels,et al.  Pleiotropic Actions of Peroxisome Proliferator-Activated Receptors in Lipid Metabolism and Atherosclerosis , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[266]  P. Wilson,et al.  Association Between the PPARA L162V Polymorphism and Plasma Lipid Levels: The Framingham Offspring Study , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[267]  P. Libby,et al.  PPAR Activators as Antiinflammatory Mediators in Human T Lymphocytes: Implications for Atherosclerosis and Transplantation-Associated Arteriosclerosis , 2002, Circulation research.

[268]  D. Kelly,et al.  Transcriptional Activation Of Energy Metabolic Switches In The Developing And Hypertrophied Heart , 2002, Clinical and experimental pharmacology & physiology.

[269]  M. Nieminen,et al.  Peroxisome proliferator-activated receptor alpha gene variants influence progression of coronary atherosclerosis and risk of coronary artery disease. , 2002, Circulation.

[270]  Christopher K. Glass,et al.  Regulation of Cytokine Expression by Ligands of Peroxisome Proliferator Activated Receptors1 , 2002, The Journal of Immunology.

[271]  T. Arinami,et al.  A Val227Ala polymorphism in the peroxisome proliferator activated receptor α (PPARα) gene is associated with variations in serum lipid levels , 2002 .

[272]  Dallas Jones,et al.  Nuclear Receptor Peroxisome Proliferator-activated Receptor α (PPARα) Is Expressed in Resting Murine Lymphocytes , 2002, The Journal of Biological Chemistry.

[273]  J. Kuromitsu,et al.  Microarray analysis of gene expression changes in mouse liver induced by peroxisome proliferator- activated receptor alpha agonists. , 2002, Biochemical and biophysical research communications.

[274]  A. Tall,et al.  Transcriptional Profiling Reveals Global Defects in Energy Metabolism, Lipoprotein, and Bile Acid Synthesis and Transport with Reversal by Leptin Treatment in Ob/ob Mouse Liver* , 2001, The Journal of Biological Chemistry.

[275]  D. Kelly,et al.  p38 Mitogen-activated Protein Kinase Activates Peroxisome Proliferator-activated Receptor α , 2001, The Journal of Biological Chemistry.

[276]  L. Moore,et al.  Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[277]  B Staels,et al.  Fibrates Suppress Bile Acid Synthesis via Peroxisome Proliferator–Activated Receptor-&agr;–Mediated Downregulation of Cholesterol 7&agr;-Hydroxylase and Sterol 27-Hydroxylase Expression , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[278]  J. Oscarsson,et al.  Effects of fatty acids and growth hormone on liver fatty acid binding protein and PPARα in rat liver , 2001 .

[279]  Robert A. Harris,et al.  Adaptive increase in pyruvate dehydrogenase kinase 4 during starvation is mediated by peroxisome proliferator-activated receptor alpha. , 2001, Biochemical and biophysical research communications.

[280]  Robert Kleemann,et al.  Negative Regulation of Human Fibrinogen Gene Expression by Peroxisome Proliferator-activated Receptor α Agonists via Inhibition of CCAAT Box/Enhancer-binding Protein β* , 2001, The Journal of Biological Chemistry.

[281]  W. Wahli,et al.  The peroxisome proliferator‐activated receptor α regulates amino acid metabolism , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[282]  J. Berger,et al.  Differential Gene Regulation in Human Versus Rodent Hepatocytes by Peroxisome Proliferator-activated Receptor (PPAR) α , 2001, The Journal of Biological Chemistry.

[283]  Daniel Metzger,et al.  Impaired skin wound healing in peroxisome proliferator–activated receptor (PPAR)α and PPARβ mutant mice , 2001, The Journal of cell biology.

[284]  M. Dumont,et al.  Effect of a six month gemfibrozil treatment and dietary recommendations on the metabolic risk profile of visceral obese men , 2001, International Journal of Obesity.

[285]  N. Blomberg,et al.  Structure of the PPARα and -γ Ligand Binding Domain in Complex with AZ 242; Ligand Selectivity and Agonist Activation in the PPAR Family , 2001 .

[286]  L. Brass,et al.  Reduction in Stroke With Gemfibrozil in Men With Coronary Heart Disease and Low HDL Cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT) , 2001, Circulation.

[287]  W. Wilkison,et al.  Identification of a subtype selective human PPARalpha agonist through parallel-array synthesis. , 2001, Bioorganic & medicinal chemistry letters.

[288]  G. Bell,et al.  Identification of three missense mutations in the peroxisome proliferator-activated receptor α gene in Japanese subjects with maturity-onset diabetes of the young , 2001, Journal of Human Genetics.

[289]  T. Willson,et al.  Differential involvement of peroxisome-proliferator-activated receptors α and δ in fibrate and fatty-acid-mediated inductions of the gene encoding liver fatty-acid-binding protein in the liver and the small intestine , 2001 .

[290]  S. Mudaliar,et al.  Peroxisome Proliferator-Activated Receptor (PPAR) γ and Retinoid X Receptor (RXR) agonists have complementary effects on glucose and lipid metabolism in human skeletal muscle , 2001, Diabetologia.

[291]  K. Tokuyama,et al.  Effects of bezafibrate on insulin sensitivity and insulin secretion in non-obese Japanese type 2 diabetic patients. , 2001, Metabolism: clinical and experimental.

[292]  G. Gibbons,et al.  Disturbances in the normal regulation of SREBP-sensitive genes in PPARα-deficient mice , 2001 .

[293]  G. Shipley,et al.  Uncoupling protein 3 transcription is regulated by peroxisome proliferator‐activated receptor α in the adult rodent heart , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[294]  J. Aberle,et al.  A polymorphism, L162V, in the peroxisome proliferator-activated receptor α (PPARα) gene is associated with lower body mass index in patients with non-insulin-dependent diabetes mellitus , 2001, Journal of Molecular Medicine.

[295]  V. Colantuoni,et al.  Fenofibrate prevents and reduces body weight gain and adiposity in diet‐induced obese rats , 2001, FEBS letters.

[296]  T. Pineau,et al.  Long-chain fatty acids regulate liver carnitine palmitoyltransferase I gene (L-CPT I) expression through a peroxisome-proliferator-activated receptor alpha (PPARalpha)-independent pathway. , 2001, The Biochemical journal.

[297]  Jerrold M. Ward,et al.  Hepatocyte Nuclear Factor 4α (Nuclear Receptor 2A1) Is Essential for Maintenance of Hepatic Gene Expression and Lipid Homeostasis , 2001, Molecular and Cellular Biology.

[298]  B. Jude,et al.  PPARα Agonists Inhibit Tissue Factor Expression in Human Monocytes and Macrophages , 2001 .

[299]  P. Libby,et al.  PPARalpha activators inhibit tissue factor expression and activity in human monocytes. , 2001, Circulation.

[300]  W. Wahli,et al.  Activation of peroxisome proliferator-activated receptors (PPARs) by their ligands and protein kinase A activators. , 2000, Molecular endocrinology.

[301]  B. Staels,et al.  Induction of IκBα Expression as a Mechanism Contributing to the Anti-inflammatory Activities of Peroxisome Proliferator-activated Receptor-α Activators* , 2000, The Journal of Biological Chemistry.

[302]  M. Prentki,et al.  Glucose Down-regulates the Expression of the Peroxisome Proliferator-activated Receptor-α Gene in the Pancreatic β-Cell* , 2000, The Journal of Biological Chemistry.

[303]  A. Soutar,et al.  The effect of peroxisome-proliferator-activated receptor-alpha on the activity of the cholesterol 7 alpha-hydroxylase gene. , 2000, The Biochemical journal.

[304]  G. Charpentier,et al.  Mutation screening of the PPARalpha gene in type 2 diabetes associated with coronary heart disease. , 2000, Diabetes & metabolism.

[305]  B. Staels,et al.  Peroxisome proliferator-activated receptors (PPARs): Nuclear receptors at the crossroads between lipid metabolism and inflammation , 2000, Inflammation Research.

[306]  T Hashimoto,et al.  Defect in Peroxisome Proliferator-activated Receptor α-inducible Fatty Acid Oxidation Determines the Severity of Hepatic Steatosis in Response to Fasting* , 2000, The Journal of Biological Chemistry.

[307]  R. Evans,et al.  Role for Peroxisome Proliferator-Activated Receptor &agr; in Oxidized Phospholipid–Induced Synthesis of Monocyte Chemotactic Protein-1 and Interleukin-8 by Endothelial Cells , 2000, Circulation research.

[308]  P. Chambon,et al.  Characterization of the Fasting-induced Adipose Factor FIAF, a Novel Peroxisome Proliferator-activated Receptor Target Gene* , 2000, The Journal of Biological Chemistry.

[309]  M. Hunt,et al.  The Peroxisome Proliferator-activated Receptor α (PPARα) Regulates Bile Acid Biosynthesis* , 2000, The Journal of Biological Chemistry.

[310]  J. Auwerx,et al.  Stimulation of PPARα Promotes Epidermal Keratinocyte Differentiation In Vivo , 2000 .

[311]  T. Ono,et al.  Constitutive Regulation of Cardiac Fatty Acid Metabolism through Peroxisome Proliferator-activated Receptor α Associated with Age-dependent Cardiac Toxicity* , 2000, The Journal of Biological Chemistry.

[312]  Bezafibrate Infarction Prevention study.  Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. , 2000, Circulation.

[313]  T. Pineau,et al.  Reduced hepatic fatty acid oxidation in fasting PPARα null mice is due to impaired mitochondrial hydroxymethylglutaryl‐CoA synthase gene expression , 2000, FEBS letters.

[314]  K. Sugimura,et al.  Human fatty acid omega-hydroxylase, CYP4A11: determination of complete genomic sequence and characterization of purified recombinant protein. , 2000, Archives of biochemistry and biophysics.

[315]  D. Kelly,et al.  Deactivation of peroxisome proliferator-activated receptor-alpha during cardiac hypertrophic growth. , 2000, The Journal of clinical investigation.

[316]  Bruno Derudas,et al.  Peroxisome Proliferator-activated Receptor α Activators Improve Insulin Sensitivity and Reduce Adiposity* , 2000, The Journal of Biological Chemistry.

[317]  T. Hudson,et al.  Molecular scanning of the human PPARa gene: association of the L162v mutation with hyperapobetalipoproteinemia. , 2000, Journal of lipid research.

[318]  J. Peters,et al.  The human peroxisome proliferator-activated receptor alpha gene: identification and functional characterization of two natural allelic variants. , 2000, Pharmacogenetics.

[319]  K. Feingold,et al.  The Acute Phase Response Is Associated with Retinoid X Receptor Repression in Rodent Liver* , 2000, The Journal of Biological Chemistry.

[320]  Sander Kersten,et al.  Roles of PPARs in health and disease , 2000, Nature.

[321]  P. Talmud,et al.  Variation in the PPARα gene is associated with altered function in vitro and plasma lipid concentrations in Type II diabetic subjects , 2000, Diabetologia.

[322]  J. Auwerx,et al.  Cross-Talk between Fatty Acid and Cholesterol Metabolism Mediated by Liver X Receptor-α , 2000 .

[323]  L. Agellon,et al.  The Murine and Human Cholesterol 7α-Hydroxylase Gene Promoters Are Differentially Responsive to Regulation by Fatty Acids Mediated via Peroxisome Proliferator-activated Receptor α* , 2000, The Journal of Biological Chemistry.

[324]  J. Magdalou,et al.  Evidence for the Presence of Peroxisome Proliferator-activated Receptor (PPAR) α and γ and Retinoid Z Receptor in Cartilage , 2000, The Journal of Biological Chemistry.

[325]  N. Socci,et al.  Leptin-specific patterns of gene expression in white adipose tissue. , 2000, Genes & development.

[326]  B. Staels,et al.  Oxidized phospholipids activate PPARα in a phospholipase A2‐dependent manner , 2000 .

[327]  J. Chiang,et al.  Peroxisome proliferator-activated receptor alpha (PPARalpha) and agonist inhibit cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription. , 2000, Journal of lipid research.

[328]  W. Wahli,et al.  Peroxisome proliferator-activated receptors: insight into multiple cellular functions. , 2000, Mutation research.

[329]  T. Osumi,et al.  The peroxisome proliferator response element (PPRE) present at positions -681/-669 in the rat liver 3-ketoacyl-CoA thiolase B gene functionally interacts differently with PPARalpha and HNF-4. , 2000, Biochemical and biophysical research communications.

[330]  D. Bishop-Bailey.  Peroxisome proliferator‐activated receptors in the cardiovascular system , 2000, British journal of pharmacology.

[331]  T. Kurtz,et al.  Ligands for the Peroxisome Proliferator-Activated Receptor-γ and the Retinoid X Receptor-α Exert Synergistic Antiproliferative Effects on Human Coronary Artery Smooth Muscle Cells , 2000 .

[332]  T. Willson,et al.  The PPARs: from orphan receptors to drug discovery. , 2000, Journal of medicinal chemistry.

[333]  T. Osumi,et al.  Characterization of the Amino-terminal Activation Domain of Peroxisome Proliferator-activated Receptor α , 1999, The Journal of Biological Chemistry.

[334]  Frank J. Gonzalez,et al.  Peroxisome Proliferator-activated Receptor α Negatively Regulates the Vascular Inflammatory Gene Response by Negative Cross-talk with Transcription Factors NF-κB and AP-1* , 1999, The Journal of Biological Chemistry.

[335]  W. Wahli,et al.  Peroxisome proliferator-activated receptors: nuclear control of metabolism. , 1999, Endocrine reviews.

[336]  J. Lehmann,et al.  A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPARalpha agonist with potent lipid-lowering activity. , 1999, Journal of medicinal chemistry.

[337]  N. Latruffe,et al.  Phosphorylation of peroxisome proliferator-activated receptor alpha in rat Fao cells and stimulation by ciprofibrate. , 1999, Biochemical pharmacology.

[338]  B. Staels,et al.  Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. , 1999, Circulation research.

[339]  H. Cohen,et al.  Repression and activation of transcription of phosphoenolpyruvate carboxykinase gene during liver development , 1999, FEBS letters.

[340]  B Staels,et al.  A truncated human peroxisome proliferator-activated receptor alpha splice variant with dominant negative activity. , 1999, Molecular endocrinology.

[341]  T. Wilt,et al.  Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. , 1999, The New England journal of medicine.

[342]  R. Daynes,et al.  Age-associated alterations in splenic iNOS regulation: influence of constitutively expressed IFN-gamma and correction following supplementation with PPARalpha activators or vitamin E. , 1999, Cellular immunology.

[343]  M. Başaranoǧlu,et al.  A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. , 1999, Journal of hepatology.

[344]  B. Spiegelman,et al.  Identification of Conserved cis-Elements and Transcription Factors Required for Sterol-regulated Transcription of Stearoyl-CoA Desaturase 1 and 2* , 1999, The Journal of Biological Chemistry.

[345]  J. Reddy,et al.  Peroxisomal and Mitochondrial Fatty Acid β-Oxidation in Mice Nullizygous for Both Peroxisome Proliferator-activated Receptor α and Peroxisomal Fatty Acyl-CoA Oxidase , 1999, The Journal of Biological Chemistry.

[346]  B. Spiegelman,et al.  An adipogenic cofactor bound by the differentiation domain of PPARγ , 1999, The EMBO journal.

[347]  J. Gimble,et al.  Effect of Peroxisome Proliferator-Activated Receptor Alpha Activators on Tumor Necrosis Factor Expression in Mice during Endotoxemia , 1999, Infection and Immunity.

[348]  D. Kelly,et al.  A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalpha-null mouse as a model of fatty acid oxidation disorders. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[349]  P. Libby,et al.  PPARα Activators Inhibit Cytokine-Induced Vascular Cell Adhesion Molecule-1 Expression in Human Endothelial Cells , 1999 .

[350]  B. Staels,et al.  Peroxisome proliterator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis , 1999 .

[351]  W. Wahli,et al.  Peroxisome proliferator–activated receptor α mediates the adaptive response to fasting , 1999 .

[352]  M. Leid,et al.  Identification of Nuclear Receptor Corepressor as a Peroxisome Proliferator-activated Receptor α Interacting Protein* , 1999, The Journal of Biological Chemistry.

[353]  J. Lehmann,et al.  Orphan nuclear receptors: shifting endocrinology into reverse. , 1999, Science.

[354]  A. Burger,et al.  Regulation of the Transcriptional Activity of the Peroxisome Proliferator-activated Receptor α by Phosphorylation of a Ligand-independent trans-Activating Domain* , 1999, The Journal of Biological Chemistry.

[355]  V. Laudet,et al.  Fibrates increase human REV-ERBalpha expression in liver via a novel peroxisome proliferator-activated receptor response element. , 1999, Molecular endocrinology.

[356]  B. Frohnert,et al.  Identification of a Functional Peroxisome Proliferator-responsive Element in the Murine Fatty Acid Transport Protein Gene* , 1999, The Journal of Biological Chemistry.

[357]  J. Tugwood,et al.  Peroxisome proliferator-activated receptor alpha: role in rodent liver cancer and species differences. , 1999, Journal of molecular endocrinology.

[358]  G. Assmann,et al.  Phytanic Acid Activates the Peroxisome Proliferator-activated Receptor α (PPARα) in Sterol Carrier Protein 2-/ Sterol Carrier Protein x-deficient Mice* , 1999, The Journal of Biological Chemistry.

[359]  D. Waxman,et al.  Cross-talk between Janus Kinase-Signal Transducer and Activator of Transcription (JAK-STAT) and Peroxisome Proliferator-activated Receptor-α (PPARα) Signaling Pathways , 1999, The Journal of Biological Chemistry.

[360]  N. Noy,et al.  Ligand selectivity of the peroxisome proliferator-activated receptor alpha. , 1999, Biochemistry.

[361]  R. Daynes,et al.  Peroxisome Proliferator-activated Receptor α Activation Modulates Cellular Redox Status, Represses Nuclear Factor-κB Signaling, and Reduces Inflammatory Cytokine Production in Aging* , 1998, The Journal of Biological Chemistry.

[362]  J Auwerx,et al.  Mechanism of action of fibrates on lipid and lipoprotein metabolism. , 1998, Circulation.

[363]  K. Griffin,et al.  A Carboxyl-terminal Extension of the Zinc Finger Domain Contributes to the Specificity and Polarity of Peroxisome Proliferator-activated Receptor DNA Binding* , 1998, The Journal of Biological Chemistry.

[364]  V. Laudet,et al.  The Nuclear Receptors Peroxisome Proliferator-activated Receptor α and Rev-erbα Mediate the Species-specific Regulation of Apolipoprotein A-I Expression by Fibrates* , 1998, The Journal of Biological Chemistry.

[365]  B. Staels,et al.  Activation of Proliferator-activated Receptors α and γ Induces Apoptosis of Human Monocyte-derived Macrophages* , 1998, The Journal of Biological Chemistry.

[366]  D. Kelly,et al.  Fatty Acids Activate Transcription of the Muscle Carnitine Palmitoyltransferase I Gene in Cardiac Myocytes via the Peroxisome Proliferator-activated Receptor α* , 1998, The Journal of Biological Chemistry.

[367]  C. Newgard,et al.  Role of peroxisome proliferator-activated receptor α in disease of pancreatic β cells , 1998 .

[368]  P. Colville-Nash,et al.  Inhibition of inducible nitric oxide synthase by peroxisome proliferator-activated receptor agonists: correlation with induction of heme oxygenase 1. , 1998, Journal of immunology.

[369]  J. Peters,et al.  Expression of Putative Fatty Acid Transporter Genes Are Regulated by Peroxisome Proliferator-activated Receptor α and γ Activators in a Tissue- and Inducer-specific Manner* , 1998, The Journal of Biological Chemistry.

[370]  W. Koenig,et al.  Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators , 1998, Nature.

[371]  C. Fan,et al.  Steatohepatitis, Spontaneous Peroxisome Proliferation and Liver Tumors in Mice Lacking Peroxisomal Fatty Acyl-CoA Oxidase , 1998, The Journal of Biological Chemistry.

[372]  R. Heyman,et al.  Transactivation by Retinoid X Receptor–Peroxisome Proliferator-Activated Receptor γ (PPARγ) Heterodimers: Intermolecular Synergy Requires Only the PPARγ Hormone-Dependent Activation Function , 1998, Molecular and Cellular Biology.

[373]  B. Okopień,et al.  Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinemia IIb. , 1998, International journal of clinical pharmacology and therapeutics.

[374]  F. Hegardt,et al.  Control of Human Muscle-type Carnitine Palmitoyltransferase I Gene Transcription by Peroxisome Proliferator-activated Receptor* , 1998, The Journal of Biological Chemistry.

[375]  J. Peters,et al.  Altered Constitutive Expression of Fatty Acid-metabolizing Enzymes in Mice Lacking the Peroxisome Proliferator-activated Receptor α (PPARα)* , 1998, The Journal of Biological Chemistry.

[376]  R. Heyman,et al.  RXR agonists activate PPARalpha-inducible genes, lower triglycerides, and raise HDL levels in vivo. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[377]  B. Seed,et al.  PPAR-γ agonists inhibit production of monocyte inflammatory cytokines , 1998, Nature.

[378]  J. Auwerx,et al.  Coordinate Regulation of the Expression of the Fatty Acid Transport Protein and Acyl-CoA Synthetase Genes by PPARα and PPARγ Activators* , 1997, The Journal of Biological Chemistry.

[379]  J. Auwerx,et al.  Alterations in Lipoprotein Metabolism in Peroxisome Proliferator-activated Receptor α-deficient Mice* , 1997, The Journal of Biological Chemistry.

[380]  L. Ferrari,et al.  Regulation of CYP4A1 and peroxisome proliferator-activated receptor alpha expression by interleukin-1beta, interleukin-6, and dexamethasone in cultured fetal rat hepatocytes. , 1997, Biochemical pharmacology.

[381]  W. Wahli,et al.  Polarity and Specific Sequence Requirements of Peroxisome Proliferator-activated Receptor (PPAR)/Retinoid X Receptor Heterodimer Binding to DNA , 1997, The Journal of Biological Chemistry.

[382]  K. Beier,et al.  TNF‐α downregulates the peroxisome proliferator activated receptor‐α and the mRNAs encoding peroxisomal proteins in rat liver , 1997 .

[383]  W. Wahli,et al.  Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. , 1997, Molecular endocrinology.

[384]  Barry M. Forman,et al.  Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ , 1997 .

[385]  C. Glass,et al.  Peroxisome proliferator-activated receptors and retinoic acid receptors differentially control the interactions of retinoid X receptor heterodimers with ligands, coactivators, and corepressors , 1997, Molecular and cellular biology.

[386]  M. Leid,et al.  Ligand-induced Peroxisome Proliferator-activated Receptor α Conformational Change* , 1997, The Journal of Biological Chemistry.

[387]  W. Wahli,et al.  The PPARα–leukotriene B4 pathway to inflammation control , 1996, Nature.

[388]  J. Reddy,et al.  Hepatocellular and Hepatic Peroxisomal Alterations in Mice with a Disrupted Peroxisomal Fatty Acyl-coenzyme A Oxidase Gene* , 1996, The Journal of Biological Chemistry.

[389]  J Auwerx,et al.  PPARalpha and PPARgamma activators direct a distinct tissue‐specific transcriptional response via a PPRE in the lipoprotein lipase gene. , 1996, The EMBO journal.

[390]  W. Wahli,et al.  The Peroxisome Proliferator-Activated Receptor a Is a Phosphoprotein: Regulation by Insulin. , 2001 .

[391]  J. Ntambi,et al.  Peroxisome proliferators induce mouse liver stearoyl-CoA desaturase 1 gene expression. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[392]  D. Jump,et al.  Peroxisome Proliferator-activated Receptor α Inhibits Hepatic S14 Gene Transcription , 1996, The Journal of Biological Chemistry.

[393]  Y. Horsmans,et al.  Pharmacodynamic activity of lipoprotein lipase and hepatic lipase, and pharmacokinetic parameters measured in normolipidaemic subjects receiving ciprofibrate (100 or 200 mg/day) or micronised fenofibrate (200 mg/day) therapy for 23 days. , 1996, Atherosclerosis.

[394]  J. Auwerx,et al.  Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice. , 1996, The Journal of clinical investigation.

[395]  G. Gores,et al.  Ursodeoxycholic acid or clofibrate in the treatment of non‐alcohol‐induced steatohepatitis: A pilot study , 1996, Hepatology.

[396]  J Auwerx,et al.  Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. , 1996, Journal of lipid research.

[397]  A. Hamsten,et al.  Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients , 1996, The Lancet.

[398]  J. Auwerx,et al.  Expression of the Peroxisome Proliferator-activated Receptor Gene Is Stimulated by Stress and Follows a Diurnal Rhythm (*) , 1996, The Journal of Biological Chemistry.

[399]  T. Leff,et al.  Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: a potential physiologic basis for their mode of action. , 1995, Journal of lipid research.

[400]  Kai Yu,et al.  Differential Activation of Peroxisome Proliferator-activated Receptors by Eicosanoids (*) , 1995, The Journal of Biological Chemistry.

[401]  T. Watanabe,et al.  Suppressive effect of growth hormone on the expression of peroxisome proliferator-activated receptor in cultured rat hepatocytes. , 1995, Research communications in molecular pathology and pharmacology.

[402]  J Auwerx,et al.  Induction of the Acyl-Coenzyme A Synthetase Gene by Fibrates and Fatty Acids Is Mediated by a Peroxisome Proliferator Response Element in the C Promoter (*) , 1995, The Journal of Biological Chemistry.

[403]  J. Auwerx,et al.  Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. , 1995, The Journal of clinical investigation.

[404]  W. Wahli,et al.  Peroxisome Proliferator-activated Receptor Mediates Cross-talk with Thyroid Hormone Receptor by Competition for Retinoid X Receptor , 1995, The Journal of Biological Chemistry.

[405]  J. Bar-Tana,et al.  Mode of Action of Peroxisome Proliferators as Hypolipidemic Drugs. , 1995, The Journal of Biological Chemistry.

[406]  T. Pineau,et al.  Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators , 1995, Molecular and cellular biology.

[407]  J. Auwerx,et al.  Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. , 1995, The Journal of clinical investigation.

[408]  B. Spiegelman,et al.  PPAR gamma 2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene , 1995, Molecular and cellular biology.

[409]  J. Auwerx,et al.  Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element. , 1994, The Journal of biological chemistry.

[410]  D. Moore,et al.  The peroxisome proliferator-activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[411]  K. Gautvik,et al.  Dexamethasone and insulin demonstrate marked and opposite regulation of the steady-state mRNA level of the peroxisomal proliferator-activated receptor (PPAR) in hepatic cells. Hormonal modulation of fatty-acid-induced transcription. , 1994, European journal of biochemistry.

[412]  D. Moore,et al.  The peroxisome proliferator activated receptor regulates malic enzyme gene expression. , 1994, The Journal of biological chemistry.

[413]  J. Auwerx,et al.  Regulation of the peroxisome proliferator-activated receptor alpha gene by glucocorticoids. , 1994, The Journal of biological chemistry.

[414]  G. Gil-Gómez,et al.  Peroxisome proliferator-activated receptor mediates induction of the mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase gene by fatty acids. , 1994, The Journal of biological chemistry.

[415]  K. Umesono,et al.  Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[416]  S Kettle,et al.  Mechanistically-based Human Hazard Assessment of Peroxisome Proliferator-induced Hepatocarcinogenesis , 1994, Human & experimental toxicology.

[417]  R. Simsolo,et al.  Effect of gemfibrozil on adipose tissue and muscle lipoprotein lipase. , 1993, Metabolism: clinical and experimental.

[418]  B. O’Malley,et al.  Identification of two mPPAR related receptors and evidence for the existence of five subfamily members. , 1993, Biochemical and biophysical research communications.

[419]  O. Mcbride,et al.  cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor. , 1993, Biochemistry.

[420]  K. Umesono,et al.  Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors , 1992, Nature.

[421]  J. Capone,et al.  Identification of a peroxisome proliferator-responsive element upstream of the gene encoding rat peroxisomal enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[422]  J. Gustafsson,et al.  Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[423]  Christine Dreyer,et al.  Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors , 1992, Cell.

[424]  J. Auwerx,et al.  Fibrates influence the expression of genes involved in lipoprotein metabolism in a tissue-selective manner in the rat. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[425]  I. Issemann,et al.  The mouse peroxisome proliferator activated receptor recognizes a response element in the 5′ flanking sequence of the rat acyl CoA oxidase gene. , 1992, The EMBO journal.

[426]  I. Issemann,et al.  Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators , 1990, Nature.

[427]  J. Huttunen,et al.  Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. , 1987, The New England journal of medicine.

[428]  H. Lithell,et al.  Elevated lipoprotein lipase activity in skeletal muscle tissue during treatment of hypertriglyceridaemic patients with bezafibrate. , 1982, Atherosclerosis.

[429]  A. Goldberg,et al.  Increase in lipoprotein lipase during clofibrate treatment of hypertriglyceridemia in patients on hemodialysis. , 1979, The New England journal of medicine.

[430]  H. Lithell,et al.  Increase of the lipoprotein‐lipase activity in human skeletal muscle during clof ibrate administration , 1978, European journal of clinical investigation.

[431]  D. Galton,et al.  CLOFIBRATE INCREASES LIPOPROTEIN-LIPASE ACTIVITY IN ADIPOSE TISSUE OF HYPERTRIGLYCERIDÆMIC PATIENTS , 1977, The Lancet.

[432]  Kyung Chul Park,et al.  A PPAR Pan Agonist, MHY2013 Alleviates Age-Related Hepatic Lipid Accumulation by Promoting Fatty Acid Oxidation and Suppressing Inflammation. , 2018, Biological & pharmaceutical bulletin.

[433]  B. Staels,et al.  PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD , 2017, Nature Reviews Endocrinology.

[434]  Georgia Salanti,et al.  Homocysteine lowering interventions for preventing cardiovascular events. , 2009, The Cochrane database of systematic reviews.

[435]  Z. Fayad,et al.  Effect of bezafibrate therapy on atherosclerotic aortic plaques detected by MRI in dyslipidemic patients with hypertriglyceridemia. , 2008, Atherosclerosis.

[436]  G. Charpentier,et al.  Mutation screening of the PPAR agene in type 2 diabetes associated with coronary heart disease , 2008 .

[437]  Béatrice Desvergne,et al.  RXR: from partnership to leadership in metabolic regulations. , 2007, Vitamins and hormones.

[438]  J. Škrha,et al.  Influence of PPAR-alpha agonist fenofibrate on insulin sensitivity and selected adipose tissue-derived hormones in obese women with type 2 diabetes. , 2007, Physiological research.

[439]  J. Škrha,et al.  Influence of PPAR-α Agonist Fenofibrate on Insulin Sensitivity and Selected Adipose Tissue-derived Hormones in Obese Women with Type 2 Diabetes , 2007 .

[440]  B. Staels.  When the Clock stops ticking, metabolic syndrome explodes , 2006, Nature Medicine.

[441]  J. Girard,et al.  Phosphorylation of PPARs: from molecular characterization to physiological relevance. , 2005, Biochimie.

[442]  C. Harvengt,et al.  Effects of clofibrate, bezafibrate, fenofibrate and probucol on plasma lipolytic enzymes in normolipaemic subjects , 2004, European Journal of Clinical Pharmacology.

[443]  John H. White,et al.  Corepressor recruitment by agonist-bound nuclear receptors. , 2004, Vitamins and hormones.

[444]  R. Smolenski,et al.  Peroxisome proliferator-activated receptor alpha is downregulated in the failing human heart. , 2003, Cellular & molecular biology letters.

[445]  W. Wahli,et al.  Sex difference in hepatic peroxisome proliferator-activated receptor alpha expression: influence of pituitary and gonadal hormones. , 2003, Endocrinology.

[446]  B. Staels,et al.  Induction of hepatic ABC transporter expression is part of the PPARalpha-mediated fasting response in the mouse. , 2003, Gastroenterology.

[447]  R. Smolenski,et al.  PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR α IS DOWNREGULATED IN THE FAILING HUMAN HEART , 2003 .

[448]  H. Sone,et al.  Dual regulation of mouse Δ5- and Δ6-desaturase gene expression by SREBP-1 and PPARα , 2002 .

[449]  Xianlin Han,et al.  The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. , 2002, The Journal of clinical investigation.

[450]  J. Auwerx,et al.  Topical Peroxisome Proliferator Activated Receptor-α Activators Reduce Inflammation in Irritant and Allergic Contact Dermatitis Models , 2002 .

[451]  M. Jaye,et al.  PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway , 2001, Nature Medicine.

[452]  B. Staels,et al.  The role of fibric acids in atherosclerosis , 2001, Current atherosclerosis reports.

[453]  G. Renier,et al.  Differential regulation of macrophage peroxisome proliferator-activated receptor expression by glucose : role of peroxisome proliferator-activated receptors in lipoprotein lipase gene expression. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[454]  J. Chiang,et al.  Peroxisome proliferator-activated receptor a (PPAR a ) and agonist inhibit cholesterol 7 a -hydroxylase gene ( CYP7A1 ) transcription , 2000 .

[455]  K. Griffin,et al.  Peroxisome proliferator activated receptor-alpha expression in human liver. , 1998, Molecular pharmacology.

[456]  W. Wahli,et al.  Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. , 1996, Annual review of cell and developmental biology.

[457]  W. Wahli,et al.  Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. , 1996, Endocrinology.

[458]  T. Pineau,et al.  Long-chain fatty acids regulate liver carnitine palmitoyltransferase I gene (L-CPT I ) expression through a peroxisome-proliferator-activated receptor α (PPARα)-independent pathway , 2022 .